迈威生物2025年净亏损9.7亿元

Core Viewpoint - Maiwei Biotech reported significant revenue growth for 2025, with total revenue reaching 663 million yuan, a year-on-year increase of 231.62%. However, the company still recorded a net loss of 970 million yuan, which is an improvement from the previous year's loss of 1.044 billion yuan [1]. Revenue Performance - The company's total revenue for the reporting period was 663 million yuan, marking a substantial increase compared to the previous year [1]. - The revenue growth was primarily driven by significant income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC., as well as a notable increase in drug sales revenue compared to the same period last year [1]. Net Loss Analysis - The net loss attributable to the parent company's shareholders was 970 million yuan, which is a reduction from the net loss of 1.044 billion yuan in the same period last year [1].